Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase…

By Yi-long Wu, Caicun Zhou, Cheng-ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, M. Hou, Jianhua Shi, K. Lee and 5 more. The Lancet Oncology, 2014

1,917 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3d7ab347b94ac093a23daf82b6ce020b6782e0df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jin-Yuan Shih
2. Shang-Gin Wu

In Pulmonary and Respiratory Medicine

1. B. Chan
2. Jin-Yuan Shih
3. B. Hughes
4. Shang-Gin Wu

Citations in the corpus

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016, neutral): “Aspartate aminotransferase elevation 14 (5) 3 (1) 15 (11) 1 (1)”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Further confirmatory trials (Table 1) compared gefitinib (42,43), erlotinib (44,45) or afatinib (46,47) to chemotherapy specifically in EGFR-mutated NSCLC rather than simply by the clinical enrichment criteria of earlier studies.”
• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, positive): “However, the patient had a good treatment response and prolonged PFS [37], and the original activating EGFR mutations of adenocarcinoma persisted in the re-biopsy SCLC specimens [38, 39].”